Skip to NavigationSkip to content

simeprevir

Janssen privy to new pricing scheme and see NICE nod

Olysio  image

Janssen’s hepatitis C drug Olysio has been approved by NICE whilst also reaching a novel ‘pay if you clear’ pricing agreement with the NHS.

The payment scheme means that NHS England will only pay for Olysio (simeprevir) if patients are effectively cured of the virus after 12 weeks of treatment, with Janssen refunding the cost for those who aren’t. Trials so far have found a cure rate of around 80% after 12 weeks of using the drug.

FDA approves Olysio

janssen image

US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority review.

Protease inhibitor Olysio (simeprevir) blocks a specific protein needed by the hepatitis C virus to replicate and is approved for use in combination with peginterferon-alfa and ribavirin.

It will be used in treatment-naïve adults with compensated liver disease - that is, a diseased liver that is still functioning - which may include cirrhosis, or patients for whom previous treatment has not been effective.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches